Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mike Wenzel

Showing results (51-60 of 213) with videos related to

Pageof 22
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|April 7, 2025
Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA Radioligand vs. Radium- 223-naïve mCRPC patientsMike Wenzel, Lena Theissen, Daniel Groener, et al.
Urologic Oncology|October 16, 2022
Efficacy of cabazitaxel in fourth or later line of therapy in metastatic castration-resistant prostate cancer: Multi-institutional real-world experience in GermanyMike Wenzel, Angelika Borkowetz, Verena Lieb, et al.
World Journal of Urology|November 2, 2024
Influence of metastatic sites and burden on oncological outcomes in patients progressing to metastatic castration resistant prostate cancerMike Wenzel, Benedikt Hoeh, Clara Humke, et al.
Theranostics|March 14, 2025
Cancer-control outcomes with [<sup>177</sup>Lu]Lu-PSMA Radioligand Therapy in elderly, frail or comorbid mCRPC patientsMike Wenzel, Carolin Siech, Cristina Cano Garcia, et al.
Urologic Oncology|July 28, 2024
Organ-confined pT2 ISUP4/5 vs. nonorgan confined pT3/4 ISUP2 vs. ISUP3 prostate cancer: Differences in biochemical recurrence-free survival after radical prostatectomyCarolin Siech, Benedikt Hoeh, Eike Rohlfsen, et al.
The Prostate|May 30, 2024
Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real-world setting of metastatic hormone-sensitive prostate cancer patientsMike Wenzel, Benedikt Hoeh, Fabienne Hurst, et al.
Urologic Oncology|July 31, 2021
The effect of race on stage at presentation and survival in upper tract urothelial carcinomaClaudia Collà Ruvolo, Mike Wenzel, Luigi Nocera, et al.
European Urology Focus|December 6, 2024
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: An Updated Network Meta-analysis Including ARANOTE DataBenedikt Hoeh, Mike Wenzel, Zhe Tian, et al.
The Prostate|July 19, 2023
Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapyMike Wenzel, Cristina C Garcia, Benedikt Hoeh, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 4, 2021
Stage and cancer-specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population-based studyClaudia Collà Ruvolo, Christoph Würnschimmel, Luigi Nocera, et al.
Pageof 22

Showing results (51-60 of 213) with videos related to

Sort By:
Pageof 22
European Journal of Nuclear Medicine and Molecular Imaging|April 7, 2025
Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA Radioligand vs. Radium- 223-naïve mCRPC patientsMike Wenzel, Lena Theissen, Daniel Groener, et al.
Urologic Oncology|October 16, 2022
Efficacy of cabazitaxel in fourth or later line of therapy in metastatic castration-resistant prostate cancer: Multi-institutional real-world experience in GermanyMike Wenzel, Angelika Borkowetz, Verena Lieb, et al.
World Journal of Urology|November 2, 2024
Influence of metastatic sites and burden on oncological outcomes in patients progressing to metastatic castration resistant prostate cancerMike Wenzel, Benedikt Hoeh, Clara Humke, et al.
Theranostics|March 14, 2025
Cancer-control outcomes with [<sup>177</sup>Lu]Lu-PSMA Radioligand Therapy in elderly, frail or comorbid mCRPC patientsMike Wenzel, Carolin Siech, Cristina Cano Garcia, et al.
Urologic Oncology|July 28, 2024
Organ-confined pT2 ISUP4/5 vs. nonorgan confined pT3/4 ISUP2 vs. ISUP3 prostate cancer: Differences in biochemical recurrence-free survival after radical prostatectomyCarolin Siech, Benedikt Hoeh, Eike Rohlfsen, et al.
The Prostate|May 30, 2024
Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real-world setting of metastatic hormone-sensitive prostate cancer patientsMike Wenzel, Benedikt Hoeh, Fabienne Hurst, et al.
Urologic Oncology|July 31, 2021
The effect of race on stage at presentation and survival in upper tract urothelial carcinomaClaudia Collà Ruvolo, Mike Wenzel, Luigi Nocera, et al.
European Urology Focus|December 6, 2024
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: An Updated Network Meta-analysis Including ARANOTE DataBenedikt Hoeh, Mike Wenzel, Zhe Tian, et al.
The Prostate|July 19, 2023
Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapyMike Wenzel, Cristina C Garcia, Benedikt Hoeh, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 4, 2021
Stage and cancer-specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population-based studyClaudia Collà Ruvolo, Christoph Würnschimmel, Luigi Nocera, et al.
Pageof 22